| This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors’ clinical recommendations (NEJM)
Remission of type 2 diabetes was generally infrequent in routine care settings but may be a reasonable goal for a subset of people who lose a significant amount of weight shortly after diagnosis (Diabetes Care)
In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy (Diabetes Care)
Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class 1 obesity, for whom surgery is not widely used (Diabetes Care)
This is the first multicountry analysis of six large contemporary population-based studies, and shows that all-cause mortality in people with type 1 diabetes has declined in recent years in most studied populations. However, excess mortality relative to the population without diabetes remains high in people with type 1 diabetes (Diabetologia)
In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era (The Lancet Diabetes & Endocrinology)
The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care (Diabetes Therapy)
These studies have established finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and CV protection and welcomed addition to the pillars of treatment to slow CKD progression in patients with T2D (Diabetes, Obesity and Metabolism)
| 
